Document text
Centers for Disease Control and Prevention
Adult Respiratory Syncytial Virus (RSV) Session
Camille Kotton, MD
Chair, Adult RSV Work Group
Advisory Committee on Immunization Practices (ACIP)
June 21, 2023
2Adult RSV Work Group Membership
ACIP Voting Members
Camille Kotton (Chair)
Keipp Talbot
Sarah Long
Ex Officio Members
Rachel Zhang (FDA)
Judy Beeler (FDA)
Nicholas Geagan (FDA)
Nadine Peart Akindele (FDA)
Sonnie Kim (NIH/NIAID)
Jeffrey Kelman (CMS)
Valerie Marshal (OIDP)CDC Co-Leads
Michael Melgar
Amadea Britton
Consultants
Robert Atmar (Baylor College of
Medicine)
Helen Chu (University of Washington)
Peter Donofrio (Vanderbilt University)
Marie Griffin (Vanderbilt University)Cynthia Lucero -Obusan (Veterans Health
Admin.)
Tracy Ruckwardt (NIH/NIAID)
Jonathan Temte (University of Wisconsin)
Liaisons
Kenneth Schmader (AGS)
Vidya Sundareshan (ACP)
Gretchen LaSalle (AAFP)
April Killikelly (NACI, PHAC)
Winnie Su (NACI, PHAC)Katherine Williams (APTR)
Ruth Lynfield (NFID)
Jennifer Heath (AIM)
Steven Pergam (IDSA)
3CDC Contributors
Coronavirus and Other Respiratory
Viruses Division
Lauren Roper
Fiona Havers
Meredith McMorrow
Diya Surie
Jennifer DeCuir
Mila Prill
Amanda Payne
Natalie Thornburg
Melissa Coughlin
Jefferson Jones
Katherine Fleming -Dutra
Ismael Ortega SanchezImmunization Safety Office
Anne Hause
David Shay
Christine Olson
Immunization Services Division
Neil Murthy
Patricia Wodi
Andrew Leidner
Jamison Pike
4Recap of Adult RSV session, February 2023
▪Economic analysis of RSV vaccination in older adults (CDC model)
▪Comparison of economic analyses of RSV vaccination in older adults (CDC
model vs. industry models)
▪Evidence to Recommendations framework for use of two RSV vaccines
(GSK and Pfizer products) in older adults
5Recent work group discussion
▪Review of Season 2 safety and efficacy data from main phase 3 trials of RSV
vaccines, as well as coadministration study results (with influenza vaccines)
▪Update to GRADE and Evidence to Recommendations for both RSV
vaccines, inclusive of Season 2 data
▪Update to economic analyses of RSV vaccination in older adults, inclusive
of Season 2 data
▪Ethics considerations of different RSV vaccine policy recommendations
6Recent work group discussion
▪Possible policy recommendations for RSV vaccination of U.S. older adults
–Should RSV vaccines be recommended for U.S. adults aged ≥65 years?
–Should RSV vaccines be recommended for U.S. adults aged 60 –64
years?
7Agenda: Wednesday June 21, 2023
▪ Pfizer safety and efficacy update, including coadministration
results
▪ GSK safety and efficacy update, including coadministration
results
▪ Economic analysis of RSV vaccination among U.S. older
adults
▪ Comparison of RSV vaccination economic analyses
performed by U. Michigan/CDC, Pfizer, and GSK
▪ Update to Evidence to Recommendations framework for
Pfizer and GSK RSV vaccines
▪ Clinical considerations for use of RSV vaccines in U.S. older
adultsDr. Alejandra Gurtman (Pfizer)
Dr. Leonard Friedland (GSK)
Dr. David Hutton (U. Michigan)
Dr. Ismael Ortega Sanchez (CDC)
Dr. Michael Melgar (CDC)
Dr. Amadea Britton ( CDC)